Katzka, D A

Objective Surveillance interval protocols after complete remission of intestinal metaplasia (CRIM) post radiofrequency ablation (RFA) in Barrett’s oesophagus (BE) are currently empiric and not based on substantial evidence. We aimed to assess the timeline, location and patterns of recurrence following CRIM to inform these guidelines. Design Data on patients undergoing RFA for BE were obtained from prospectively maintained databases of five (three USA and two UK) tertiary referral centres. RFA was performed until CRIM was confirmed on two consecutive endoscopies. Results 594 patients achieved CRIM as of 1 May 2017. 151 subjects developed recurrent BE over a median (IQR) follow-up of 2.8 (1.4–4.4) years. There was 19% cumulative recurrence risk of any BE within 2 years and an additional 49% risk over the next 8.6 years. There was no evidence of a clinically meaningful change in the recurrence hazard rate of any BE, dysplastic BE or high-grade dysplasia/cancer over the duration of follow-up, with an estimated 2% (95% CI −7% to 12%) change in recurrence rate of any BE in a doubling of follow-up time. 74% of BE recurrences developed at the gastro-oesophageal junction (GOJ) (24.1% were dysplastic) and 26% in the tubular oesophagus. The yield of random biopsies from the tubular oesophagus, in the absence of visible lesions, was 1% (BE) and 0.2% (dysplasia). Conclusions BE recurrence risk following CRIM remained constant over time, suggesting that lengthening of follow-up intervals, at least in the first 5 years after CRIM, may not be advisable. Sampling the GOJ is critical to detecting recurrence. The requirement for random biopsies of the neosquamous epithelium in the absence of visible lesions may need to be re-evaluated.

SummaryBackgroundCurrent management of refractory benign oesophageal strictures with endoscopic dilations and stenting leads to resolution of dysphagia in only 30% of patients. Oesophageal self‐dilation may be an alternative.AimTo evaluate the efficacy and safety of oesophageal self‐dilation at a tertiary referral centre.MethodsWe conducted a retrospective review of patients with refractory benign oesophageal strictures who participated in oesophageal self‐dilation at Mayo Clinic (Rochester, MN, USA) between 2003 and 2017. Clinical data including stricture characteristics, Dakkak and Bennett Dysphagia Score, number and dates of endoscopies, and complications were collected. A two‐tailed paired Student's t test was used to compare the measures of efficacy, with differences considered significant at a 5% probability level.ResultsWe identified 52 patients with refractory strictures treated with self‐dilation. The median number of endoscopic interventions was reduced from 9.5 (range 5‐30) to 0 (range 0‐3) within 12 months before and after self‐dilation, respectively (P < 0.0001). A median intervention‐free interval of 417 days (IQR 256‐756 days) was observed. The mean dysphagia score at baseline was 2.5 (95% CI 2.2‐2.8) and 0.33 (95% CI 0.11‐0.53) after self‐dilation. 23 of 27 (85%) patients who received enteral nutrition prior to self‐dilation had their feeding tubes removed.ConclusionsOesophageal self‐dilation is an effective way of maintaining oesophageal patency in refractory benign oesophageal strictures, with safety comparable to current standard of care. Prospective studies are needed to further validate the role of self‐dilation in treatment of refractory benign oesophageal strictures.